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Abstract
The ligand for CD40 is expressed on activated T lymphocytes
and delivers contact-dependent activation signals to B lympho-
cytes. The mechanisms regulating CD40 ligand gene expres-
sion are largely unknown. Optimal expression of CD40 ligand
required activation of protein kinase C and a rise in intracellu-
lar calcium concentration. CD40 ligand expression was inhib-
ited by pretreatment ofT cells with cyclosporin A. Cyclosporin
A analogues inhibited CD40 ligand expression with a potency
mirroring the ability of each compound to inhibit calcineurin
activity, indicating that calcineurin plays a key role in CD40
ligand gene expression. Cyclosporin A inhibited IL4-driven
CD40 ligand-dependent IgE isotype switching in PBMC but
did not inhibit IgE synthesis induced by CD40 mAb plus IL-4.
PBMC derived from transplant patients receiving cyclosporin
A failed to express CD40 ligand upon stimulation. These re-
sults suggest that patients receiving cyclosporin A may be defi-
cient in CD40 ligand-dependent T cell help. (J. Clin. Invest.
1994. 93:1315-1320.) Key words: gene activation * calcineurin-
transcription factors * transplantation - immunosuppressants
Introduction
Humoral immunity is critically dependent on interaction be-
tween T and B lymphocytes. T cells secrete cytokines necessary
for B cell differentiation and activate B cells in a contact-de-
pendent manner (1). A prime candidate for the T cell surface
molecule that delivers the contact-dependent signal is the re-
cently described ligand for the B cell antigen CD40 (2-5). The
CD40 ligand (CD40L)' is a 39-kD type II membrane glycopro-
tein expressed on activated T cells. It is homologous to tumor
necrosis factor (4), while its counterreceptor on B cells, CD40,
is a member of the tumor necrosis factor receptor/nerve
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1. Abbreviations used in this paper: [Ca2+]i, intracellular calcium;
CD40L, CD40 ligand; CsA, cyclosporin A; IL-2Ra, IL-2 receptor alpha
chain; NF-AT, nuclear factor of activated T cells; PKC, protein kinase
C; sCD40, soluble CD40.
growth factor receptor family (6). Engagement ofCD40 on B
cells by monoclonal antibody or by CD40L results in B cell
activation, proliferation, aggregation, and immunoglobulin
isotype switching (2, 4, 7-11). Soluble forms of CD40
(sCD40) inhibit T cell-dependent B cell activation and immu-
noglobulin isotype switching (3, 12). We ( 13, 14) and others
( 15-18) have recently reported that a defect in the gene encod-
ing CD40L is responsible for X-linked immunoglobulin defi-
ciency with normal or elevated IgM (X-linked hyper IgM).
These patients are unable to synthesize immunoglobulins
other than IgM or IgD ( 19, 20), suggesting that interaction
between CD40 on B cells and its ligand on activated T cells is
critical for immunoglobulin isotype switching. They also suffer
from recurrent infections, particularly Pneumocystis carinji
pneumonia, autoimmune disease, and lymphoproliferative
disease (21 ). The role ofCD40L in preventing these diseases is
unknown. An understanding ofthe mechanisms regulating the
expression ofCD40L in T cells is essential to define its role in
the immune response. In this report, we demonstrate that acti-
vation ofprotein kinase C (PKC) and ofcalcineurin is required
for CD40L gene expression and that cyclosporin A (CsA) in-
hibits CD40L gene expression and CD40L-dependent T cell
function.
Methods
Cells and reagents. PBMC and T cells were isolated from healthy volun-
teers or from transplant patients receiving CsA as previously described
( 1 ). T cells were > 98% CD3 positive as determined by flow cytometry.
PMA, 20 ng/ml, and ionomycin, 0.5 ,gM, were obtained from Calbio-
chem-Novabiochem Corp. (San Diego, CA). CsA was kindly provided
by Sandoz Inc. (East Hanover, NJ). CsA analogues MeBm2t '-CsA and
MeAla6-CsA were previously described (22).
Cell surface staining andflow cytometry. Cell surface staining for
CD40L was performed 6 h after stimulation, unless otherwise indi-
cated, using sCD40, a product of fusion ofcDNA segments encoding
the extracellular domain of CD40 (6) to genomic DNA segments en-
coding human IgG, (3) as previously described ( 13 ). sCD44, a product
of fusion of cDNA segments encoding the extracellular domain of
CD44 (23) to genomic DNA segments encoding human IgG, (24),
was used as an isotype control. Cell surface expression of the IL-2
receptor alpha chain (IL-2Ra) was determined 24 h after stimulation
using a fluorescein-labeled CD25 mAb (Beckton Dickinson Immuno-
cytometry Systems, Mountain View, CA). Stained cells were analyzed
by flow cytometry on a FACScang (Beckton Dickinson Immunocytom-
etry Systems).
Northern blot analysis. Total RNA was extracted from stimulated
T cells at 3 h after stimulation, unless otherwise indicated, and North-
ern blot analysis was performed as previously described ( 13 ). Northern
blots were hybridized with a random primer 32P-labeled (Pharmacia
LKB Biotechnology Inc., Piscataway, NJ) human CD40L probe (gift
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of Dr. A. Aruffo, Bristol-Myers Squibb Pharmaceutical Research Insti-
tute, Seattle, WA), human IL-2 probe (American Type Culture Collec-
tion, Rockville, MD), and human IL-2Ra probe (gift of Dr. W.
Greene, Gladstone Institute, San Francisco, CA).
IgE assay. Induction ofIgE synthesis was performed and assayed as
previously described (1). PBMC were stimulated with 5 ng/ml recom-
binant IL4 (R&D Systems, Inc., Minneapolis, MN) or with IL-4 plus
5 /g/ml CD40 mAb 626.1 (25) (gift of Dr. S. M. Fu, University of
Virginia School ofMedicine, Charlottesville, VA). 100 ng/ml CsA was
added to the cultures as indicated. Culture supernatants were collected
on day 10 and assayed for IgE as described ( 1). Background IgE levels
were detected in the presence of 100 Ag/ml cycloheximide and were
always < 500 pg/ml. The average of two replicate samples is given in
the results and represents net IgE synthesis above background.
Patients. Three patients receiving CsA were studied after obtaining
informed consent. The first patient (CsA patient 1) was a 12-yr-old
male who was studied before a kidney transplant. PBMC were derived
from blood samples obtained before and 3 h after a single dose of 4
mg/kg CsA. He had not received any other immunosuppressant at the
time of the study. CsA patient 2 was a 19-yr-old female, and CsA pa-
tient 3 was a 15-yr-old male, both of whom were receiving CsA after
kidney transplantation and, at the time of the study, had trough blood
CsA levels of 124 and 84 ng/ml (whole blood HPLC), respectively.
Both patients were also receiving 15 mg prednisone every other day.
Control subjects included healthy adults and a 20-yr-old female asth-
matic patient who was receiving 15 mg of prednisone every other day.
Results
Activation ofT cells via the T cell receptor (antigen receptor)/
CD3 complex results in a signaling cascade leading to the phos-
phorylation ofphospholipase Cy on tyrosine residues (26-28).
Phospholipase C-y initiates the hydrolysis ofphosphatidylinosi-
tol bisphosphate into diacylglycerol and inositol trisphosphate
(29, 30) which activate PKC and induce a sustained rise in
intracellular calcium ([Ca2+]i), respectively (31-33). We ex-
amined the role of PKC and [Ca2+]i in the expression of
CD40L. Direct activation of PKC with PMA resulted in no
detectable expression ofCD40L (data not shown). lonomycin,
at concentrations which increase [Ca2+]i without activating
PKC (<0.5 IiM) (34), resulted in minimal expression of
CD40L (' 6%). Maximal expression of CD40L (> 60%) oc-
curred upon stimulation with both PMA and ionomycin, indi-
cating that activation ofPKC and a rise in [Ca2+]i are required
for optimal expression of CD40L. Fig. 1 A shows that CD40L
can be detected on the surface of T cells as early as 3 h after
stimulation with PMA and ionomycin. CD40L surface expres-
sion peaked at 6 h after stimulation, started to decline by 8 h,
and was barely detectable by 16 h. Northern blot analysis of
PMA- and ionomycin-induced CD40L mRNA in T cells is
shown in Fig. 1 B. CD40L mRNA was detected as early as 1 h
after stimulation, peaked at 3 h, and had decreased by 6 h after
stimulation, consistent with the kinetics ofCD40L surface ex-
pression.
The increase in [Ca2"]i that results from engagement ofthe
T cell receptor/CD3 complex causes the activation of Ca2"/
calmodulin-dependent enzymes including the protein phos-
phatase calcineurin. Calcineurin plays a key role in signal
transduction in T cells (35, 36). Calcineurin dephosphorylates
the cytoplasmic subunit ofthe transcription factor, nuclear fac-
tor ofactivated T cells (NF-AT) (37, 38), which translocates to
the nucleus where together with other proteins it forms a func-
tionally active NF-AT complex that regulates the transcription
ofthe IL-2 gene (39). The activity ofcalcineurin can be modu-
lated by complexes of immunosuppressant drugs and their en-
dogenous immunophilins, a family of proteins which bind im-
munosuppressants. One such immunosuppressant is CsA, a
natural microbial product which binds to cyclophilin (40).
The CsA/cyclophilin complex binds to calcineurin and in-
hibits its phosphatase activity (41, 42). To evaluate the role of
calcineurin in the signal transduction pathway leading to the
expression of CD40L, we examined the effect of CsA on the
expression of CD40L in T cells. Fig. 2 shows that increasing
concentrations of CsA inhibited the surface expression of
CD40L induced by PMA and ionomycin. Peak inhibition of
CD40L surface expression occurred at a concentration of 100
ng/ml of CsA, with no further inhibition detected at higher
concentrations. In contrast, CsA did not affect the surface ex-
pression of IL-2Ra, except for a minimal decrease in the mean
fluorescence intensity ofIL-2Ra at high concentrations ofCsA.
CsA inhibited the induction of CD40L mRNA induced by
PMA and ionomycin (Fig. 3). As previously reported (43),
CsA inhibited the expression of IL-2 mRNA. Peak inhibition
ofCD40L and IL-2 mRNA by CsA occurred at a concentration
of 100 ng/ml. The induction of both 3.5- and 1.5-kb IL-2Ra
mRNA transcripts (44,45) by PMA and ionomycin was mini-
mally affected by CsA except at higher concentrations. Since
mRNA was obtained at 3 h, the inhibition of IL-2Ra mRNA
was probably due to inhibition by CsA (46) rather than to
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Figure 1. Kinetics ofCD40L expression by
PMA and ionomycin. T cells were stimu-
lated by PMA and ionomycin for the indi-
cated periods of time. (A) Cell surface
staining for CD40L. CD4OL (continuous
lines) was detected on the surface ofT cells
at 3 h ( 15%), peaked at 6 h (60%), and
3 6 16 started to decline by 8 h (50%) with mini-
mal expression ofCD40L remaining by 16
_'~ h (< 5%) after stimulation. There was no
detectable binding ofsCD44 (dotted lines)
at any time point. (B) Northern blot anal-
ysis of CD40L mRNA expression. CD40L
mRNA was detected as early as 1 h, peaked
at 3 h, and decreased by 6 h after stimula-
tion. Ethidium bromide staining of 18S and
28S RNA is shown to illustrate the relative
concentrations of RNA.
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Figure 2. Inhibition ofCD40L surface expression by CsA. T cells were preincubated with medium alone or with the indicated concentrations of
CsA for 1 h before stimulation with PMA and ionomycin. CD40L and CD25 are shown by a continuous line, and relevant isotype controls are
shown by a dotted line. CsA inhibited cell surface expression ofCD40L in T cells in a concentration-dependent manner. CD40L was expressed by
62% ofthe T cells in the absence ofCsA and decreased to 58, 51, 4, and 8% with 1, 10, 100, and 1,000 ng/ml CsA, respectively. IL-2Ra expres-
sion was minimally affected by CsA. All stimulated T cells expressed IL-2Ra in the presence or absence of CsA. CsA caused a minimal decrease
in the mean fluorescence intensity ofIL-2Ra ( 144 in untreated vs 105 at 1 qg/ml CsA). The results are representative ofthree different experiments.
of its receptor (47). Inhibition of CD40L expression by CsA
was not due to inhibition of IL-2 expression because addition
ofIL-2 (100 U/ml) did not reverse CsA-mediated inhibition of
CD40L mRNA or surface expression (data not shown).
The role of calcineurin in CD40L expression was further
investigated using analogues ofCsA with different affinities for
cyclophilin and calcineurin. MeBm2t '-CsA, which has a much
lower affinity for cyclophilin than CsA (K, 500 nM vs 6.0) but
whose cyclophilin complex has a higher affinity for calcineurin
(Ki 13 nM vs 40) (22), inhibited PMA- and ionomycin-in-
duced CD40L surface expression (Fig. 4). MeBm2t'-CsA at
150 ng/ml almost completely inhibited PMA- and ionomycin-
induced CD40L expression and therefore was only slightly less
active than CsA despite an 80-90-fold weaker affinity for cy-
clophilin. MeAla6-CsA, which has a slightly lower affinity for
cyclophilin than CsA (Ki 9.0 nM vs 6.0) but whose cyclophilin
complex has a much lower affinity for calcineurin (K, > 1
x 103 nM vs 40) (22), did not inhibit PMA- and ionomycin-
induced CD40L surface expression even at concentrations as
high as I ,ug/ml (Fig. 4). These results indicate that calcineurin
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Figure 3. Inhibition of
CD40L mRNA expres-
sion by CsA. T cells
were preincubated with
the indicated concentra-




and IL-2 mRNA ex-
pression in a concentra-
tion-dependent manner.
IL-2Ra mRNA expres-
sion was minimally af-
fected by CsA. Ethi-
dium bromide staining
of 18S and 28S RNA
is shown to illustrate the
relative concentrations
of RNA. The results are
representative of three
different experiments.
has a direct role in the signaling pathway regulating CD40L
expression.
The functional importance of CsA-induced inhibition of
CD40L expression was investigated by assessing the effect of
CsA on immunoglobulin isotype switching to IgE. IL-4-in-
duced IgE isotype switching in PBMC is T cell dependent (1)
and is inhibited by sCD40 (12), indicating that CD40L expres-
sion by T cells plays a critical role in T cell-dependent IL-4-
driven IgE isotype switching. Table I shows that CsA inhibited
T cell-dependent IL-4-induced IgE synthesis in PBMC de-
rived from three different individuals. The effect of CsA was
exerted at the T cell level because CsA did not inhibit T cell-in-
dependent IgE synthesis induced by CD40 mAb and IL-4.
Therefore inhibition ofCD40L expression by CsA is associated
with inhibition of CD40L-mediated T cell-dependent B cell
function.
Finally, we investigated CD40L expression in PBMC de-
rived from CsA-treated transplant recipients. One patient was
studied before and 3 h after the administration of a single dose
of4 mg/kg CsA within the period when blood CsA levels peak,
2-4 h after oral administration (48). Fig. 5 A shows that PBMC
derived from the patient before the administration of CsA ex-
pressed CD40L after stimulation with PMA and ionomycin.
Administration of a single dose of CsA inhibited, within 3 h,
CD40L expression in PBMC. This effect was selective to
CD40L because administration of CsA did not inhibit PMA-
and ionomycin-induced IL-2Ra expression. Two other kidney
transplant patients who were receiving CsA and low dose alter-
nate day prednisone were also studied. In contrast to PBMC
derived from healthy adult subjects or from an asthmatic pa-
tient receiving equivalent doses of alternate day steroids,
PBMC derived from the transplant patients receiving CsA and
alternate day steroids failed to express CD40L on their surface
upon stimulation with PMA and ionomycin (Fig. 5 B). PBMC
from patients and controls expressed IL-2Ra normally. There-
fore, administration ofCsA in vivo inhibits PMA- and ionomy-
cin-induced CD40L expression in PBMC.
Discussion
Our results suggest that CD40L gene expression in T lympho-
cytes is under strict regulatory control. Both activation ofPKC
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Figure 4. Effect of CsA analogues on the expression of
CD40L. T cells were preincubated with medium alone
or with increasing concentrations of CsA or its analogues
MeBm2t '-CsA and MeAla6-CsA for 1 h before stimula-
tion with PMA and ionomycin. The relative affinities of
CsA and its analogues to cyclophilin and to calcineurin
are shown (22). MeBm2t '-CsA inhibited CD4OL expres-
sion by 60% at 100 ng/ml (data not shown) and by 85%
at 150 ng/ml. However, MeAla6-CsA did not inhibit
CD40L expression at concentrations ranging from 100
ng/ml to 1 zg/ml (data for 1 jlg/ml shown). Binding of
sCD44 and sCD40 are shown in dotted and continuous
lines, respectively. The results are representative of three
different experiments.
and a rise in [Ca2"Ji are required for CD40L gene expression.
CD40L mRNA is detectable as early as 1 h after stimulation
but disappears by 16 h. Similarly, CD40L surface expression is
detectable as early as 3 h after stimulation and is barely detect-
able by 16 h.
CsA inhibited CD40L mRNA and surface expression with-
out significantly affecting IL-2Ra mRNA or surface expres-
sion. CsA appears to exert its inhibitory effect through inhibi-
tion of the Ca2+/calmodulin-dependent protein phosphatase
calcineurin. The ability of CsA analogues to inhibit CD40L
expression correlated with the ability of each compound to
inhibit calcineurin activity. These results indicate that calci-
neurin plays a key role in the activation ofCD40L gene expres-
sion.
Experiments involving overexpression of calcineurin in
Jurkat T cells suggest that NF-AT is a target of calcineurin
(35). More recently, NF-AT has been shown to be a substrate
for calcineurin in vitro (38). It is therefore likely that NF-AT
may play an important role in the regulation oftranscription of
the CD40L gene. A role for NF-AT may also explain the re-
quirement for activation of PKC. PKC activates several nu-
clear transcription factors including members of the fos and
jun family ofproteins which participate in a functional NF-AT
Table I. Effect ofCsA on CD40L-dependent IgE Isotype Switching
IL-4 CD40 mAb plus IL-4
Subject Medium - +CsA - +CsA
1 290 13,900 2,700 24,300 28,200
2 100 27,700 20 22,900 24,000
3 10 4,300 50 37,800 39,300
PBMC derived from three healthy volunteers were stimulated for IgE
synthesis (picograms per milliliter) as described in Methods. CsA was
added where indicated at a concentration of 100 ng/ml. CsA inhibited
IL-4-induced CD40L-dependent IgE synthesis but did not inhibit T
cell-independent IgE synthesis induced by CD40 mAb plus IL-4.
complex (49-51 ). However, it is also possible that other tran-
scription factors activated by calcineurin and/or by PKC, such
as NF-IL2A (35) may play an important role in the expression
of the CD40L gene. The exact determination of the regulatory
elements which control transcription ofthe CD40L gene awaits
detailed characterization of the human CD40L 5' regulatory
region. Preliminary data generated in our laboratory indicate
the presence of NF-AT-like sequences in the 5' region of the
mouse CD40L gene and that nuclear extracts obtained from
activated T cells bind to these sequences in electromobility
shift assays. This supports the notion that CsA may inhibit
CD40L expression by inhibiting calcineurin-dependent NF-
AT activation.
Inhibition of CD40L expression by CsA prevented T cells
from delivering CD40L-dependent signals to B cells. The in-
duction ofIgE synthesis in PBMC is T cell dependent (1 ) and is
mediated by CD40L (12). In contrast, CD40 mAb and IL-4
induce T cell-independent IgE synthesis. CsA inhibited T cell-
dependent IL-4-driven IgE synthesis in PBMC but did not
inhibit IgE synthesis induced by CD40 mAb and IL-4. These
results indicate that CsA inhibited CD40L-dependent IgE iso-
type switching.
Inhibition ofCD40L expression by CsA may have implica-
tions for patients receiving CsA. PBMC derived from trans-
plant patients receiving CsA failed to express CD40L upon
stimulation with PMA and ionomycin. Inhibition of CD40L
expression was not due to the concurrent use of steroids be-
cause PBMC derived from an asthmatic patient, receiving an
equivalent dose of alternate day steroids, expressed CD40L
upon stimulation. In addition, one of the three patients was
studied after receiving one dose ofCsA and before the adminis-
tration of steroids. It is therefore likely that T lymphocytes, in
transplant patients receiving CsA, are unable to interact with B
cells through the CD40L/CD40 axis in vivo. Since CD40L is
essential for immunoglobulin isotype switching ( 1 3), patients
receiving CsA may not be able to undergo immunoglobulin
isotype switching in response to newly encountered antigens.
Administration of intravenous immunoglobulin may decrease
the frequency ofinfections in these patients. This may be partic-
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Figure 5. Administration of CsA in vivo inhibits CD40L in PBMC. PBMC were stained for CD40L 6 h after stimulation with PMA and iono-
mycin and for IL-2Ra 24 h after stimulation. CD4OL and CD25 are shown by a continuous line, and relevant isotype controls are shown by a
dotted line. (A) PBMC derived from a transplant patient expressed CD4OL before the administration ofCsA but not 3 h after the administration
ofa single dose ofCsA. IL-2Ra expression was not inhibited by CsA. (B) PBMC derived from two transplant patients receiving CsA and alternate
day steroids failed to express CD4OL but expressed IL-2Ra normally. PBMC derived from control subject and from an asthmatic patient re-
ceiving alternate day steroids expressed CD4OL and IL-2Ra after stimulation.
ularly significant in pediatric patients who may not have had
the opportunity to develop a wide range of antibodies before
receiving CsA. Further studies are needed to demonstrate an
effect of CsA on in vivo antibody responses.
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